Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
RESMALCHIP
MALARIA
Framework programme: 5
Project number:
QLK2-CT-2002-01503
EC contribution: € 1 292 000
Duration: 36 months
Type: RS
Starting date: 1 January 2003
Graphic element Development of a Malaria-Resistant DNA Chip as a Public Health Tool for the Management of Plasmodium Falciparum Malaria Drug Resistance
Keywords: DNA chips; malaria; drug resistance

Summary:

This project aims at evaluating a newly developed DNA micro array for drug resistance monitoring in affected areas. Results will allow the dynamics of drug resistance to be captured and to forecast its development by establishing a community-based genetic resistance index, providing tools for rational and evidence-based decisions on the optimal use of drugs. The relationship between in vivo drug sensitivity and in vitro susceptibility to several anti-malarials, and the prevalence of multiple SNPs providing correlates for clinical resistance will be assessed. Sequencing will identify additional informative codons.

Problem:

The genetic diversity of malaria parasites is a major obstacle in the development of rational control strategies against this poverty related disease. Increase of health threatening drug resistance must be monitored and prevented to protect introduced drugs.

Aim:

The aims of this project are:

  1. to develop a sensitive, standardised tool for large-scale molecular epidemiological studies on Plasmodium falciparum drug resistance based on a DNA chip detecting SNPs
  2. to further document nucleotide polymorphism of genes associated with drug resistance in field samples and develop novel markers
  3. to establish a genetic resistance index (GRI) in several malaria endemic sites all over the world
  4. to coordinate efforts of European molecular epidemiologists working in different field sites to achieve a worldwide multi-locus survey of genes involved in resistance against major anti-malarial drugs
  5. to transfer innovative, high throughput technology, and provide training to malaria endemic countries to establish efficient tools for drug policy decision-making.

Expected results:

During the initial phase of the project, a prototype SNP analysis chip will be developed into an applicable tool. This includes the establishment of robust SOPs, inclusion of and verification of newly identified SNP sites, as well as an evaluation against currently used SNP analysis methods. In parallel, health centre and community surveys in the respective field sites will be set up by field teams. Furthermore, studies on resistance markers for artemisinin derivatives and large-scale sequencing on known resistance markers will be conducted from the beginning of the project onwards. As soon as health centre and community surveys have been set up, in vitro drug sensitivity studies will be performed. Upon conducting the first community surveys, samples will be prepared according to standard methods for molecular genotyping and analysed using the produced SNP micro array, but will also be tested against RFLP-based SNP analysis. Also during this process, technology transfer will take place in two selected field sites with appropriate infrastructure. Optimisation and the addition of new marker SNPs to the micro array system will be ongoing throughout the process. Quality control and further system validation will be performed by repeating approximately 10% of samples for SNP micro array analysis, but also for comparative analysis using classical SNP analysis methods.

During the analysis process, software will be developed (together with the bioinformatics units of STI, IP, and CMDT). All data will be entered electronically into a database and upon first closure (after the first round of surveys), the proposed genetic resistance index will be calculated and a predictive model will be established and tested.

Potential applications:

Results should allow forecasting of the development of malarial drug resistance through the establishment of a community-based genetic resistance index, providing tools for rational and evidence-based decisions on optimal use of antimalarial drugs.

Coordinator:

Virgílio E. do Rosário
Centro de Malária e Outras Doenças Tropicais
Instituto de Higiene e Medicina Tropical
Rua da Junqueira, 96
1349-008 Lisbon
Portugal
Tel: +351-1-362 24 58
Fax: +351-1-362 24 58
E-mail: cmdt@ihmt.unl.pt

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Odile Mercereau-PuijalonInstitut Pasteur
25 rue du ROUX
FR-75724 Paris Cedex 15
France
3Hans-Peter Beck and Ingrid FelgerSwiss Tropical Institute
Socinstrasse 57
CH-4051 Basel
Switzerland
4Anders BjorkmanKarolinska Institutet, Department of Medicine
Unit of Infectious Diseases Karolinska Hospital
SE-171 77 Stockolm
Sweden

 
 
top
Graphic element